Full circle: the Synchron BCI journey — from $10M Series A first human implant (2019) to $200M Series D (2025) commercialization
Summary
A longitudinal analysis of Synchron's funding and clinical milestone progression: $10M Series A (2019) with first human implant and motor cortex electrophysiology via blood vessel; FDA Breakthrough Device Designation (2020); Khosla $40M Series B (2021) with world's first social media post from BCI user Philip; $75M Series C (2022) from Bill Gates, Jeff Bezos, ARCH; COMMAND EFS completion with 6/6 safety endpoint; Apple BCI-HID native integration; $200M Series D (2025) led by Double Point with Qatar Investment Authority, Australia NRF, Protocol Labs; next-generation whole-brain transcatheter interface development. Total disclosed funding: $345M. Reported valuation: approximately $1 billion.
Why it matters
Synchron's progression from first human implant to $345M total funding in six years, with sovereign wealth fund and government fund participation in the most recent round, is the most complete documented case study in BCI commercialization strategy. The endovascular approach's safety advantage over cortical implants — consistently borne out in the clinical data — validates the strategic decision to prioritize minimally invasive access over electrode count.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial